Integra's Prelim Results Disappoint - Analyst Blog
January 06 2012 - 5:00AM
Zacks
Integra LifeSciences
Holdings Corporation (IART) reported disappointing
preliminary results for the fourth quarter and full year 2011.
Integra expects to report total
revenue in the range of $202–$203 million, way below the previously
announced guidance of $208.5–223.5 million. Sluggish sales during
the quarter resulted from the inventory reduction initiatives by
the company’s instrument distributors, worldwide weaker economy and
disappointing sales of Extremity Reconstruction products in the
domestic market. Based on this initial guidance, the company’s
fiscal 2011 revenues are expected to be around $778.5–779.5 million
(lower than the guided range of $785–$800 million).
Adjusted EPS in the fourth quarter
is expected in the range of 65–70 cents, lagging considerably from
the previously stated range of 75–83 cents. Fiscal 2011 adjusted
EPS of $2.74–$2.79 also compared unfavorably with the previously
announced adjusted EPS outlook of $2.88–$2.96. Earlier, while
reporting the third quarter result, Integra anticipated the
acquisition of Ascension Orthopedics (acquired in October 2011) to
dilute its adjusted EPS by 5–6 cents in the fourth quarter.
The company also lowered its 2012
revenue guidance. Integra currently expects 2012 sales to increase
roughly 8% on a constant currency basis, and 7% on a reported basis
over 2011 revenues, which is well below than the earlier provided
guidance of 10%. This was in the wake of weak fourth quarter result
combined with stronger domestic currency compared to Euro, volatile
international economy and lower growth expectations for the
domestic extremity product lines.
For the past few quarters, Integra
has been witnessing several headwinds in the form of weakness in
the extremities and spine markets leading to softer procedural
volume, tough competitive environment in global knee and hip
replacement market, challenging macroeconomic environment in Europe
and continued softness in the US leading to lower sales in Spine
and Orthobiologics.
To worsen the situation, Integra
recently received a warning letter from the US Food and Drug
Administration (FDA) pertaining to quality systems and compliance
issues at its collagen manufacturing facility in Plainsboro, New
Jersey. Earlier in August, the company received a Form 483
observation from the FDA regarding manufacturing concerns at this
collagen manufacturing facility. Collagen products currently
represent roughly 23% of total sales and are manufactured at two
facilities (the second in Puerto Rico). We are anxious regarding
the FDA warning letter as it may weigh down the stock further.
However, the company is taking
several steps to navigate through these difficulties. Earlier in
December, the company saw a change at its helm with the appointment
of Mr. Peter Arduini as the new President and Chief Executive
Officer. Mr. Arduini was earlier the President of Medication
Delivery at Baxter Healthcare, a $4.8 billion global business of
Baxter International (BAX).
Integra faces direct competition in
the medical instruments & supplies industry from major players
like Medtronic (MDT) and Stryker
Corp. (SYK). Currently, the company retains a Zacks #3
Rank (Short-term ‘Hold’). Considering the company’s business
model and fundamentals, we have a long-term ‘Neutral’
recommendation on the stock.
BAXTER INTL (BAX): Free Stock Analysis Report
INTEGRA LIFESCI (IART): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
STRYKER CORP (SYK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From May 2024 to Jun 2024
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From Jun 2023 to Jun 2024